Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery (SLIP)
Primary Purpose
Blood Glucose, Coronary Artery Bypass, Insulin
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
LIBERAL
Sponsored by

About this trial
This is an interventional treatment trial for Blood Glucose focused on measuring Blood Glucose, Insulin/Administration and Dosage, Coronary Artery Bypass
Eligibility Criteria
Inclusion Criteria:
- All diabetic patients going for isolated, non-emergent CABG surgery at Inova Fairfax Hospital (IFH).
- Non diabetic patients going for isolated, non-emergent CABG Surgery at IFH that are found to have a finger stick blood glucose > 150 mg/dl, either pre-operative, during the procedure or post-operatively.
- Those patients that meet Inclusion Criteria #1 OR #2 AND have been started on an insulin infusion while in the operative room will be enrolled.
Exclusion Criteria:
- Patients that are not undergoing CABG surgery.
- Patients that post-CABG surgery are not on an insulin infusion.
- Patients that are undergoing other procedures in addition to CABG will be excluded. (ie. CABG + valve repair)
Sites / Locations
- Inova Fairfax Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
STRICT Glucose Control (80-120 mg/dL)
LIBERAL (Target Glucose:121-180 mg/dL)
Arm Description
The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
Outcomes
Primary Outcome Measures
Operative death, major adverse cardiac events (death, myocardial infarction, re-vascularization), re-operation, Cerebrovascular accident, Deep Sternal Wound Infection, Prolonged Ventilatory Support, Acute Renal Failure, and prolonged inotropic support.
Secondary Outcome Measures
The second pre-specified endpoint will be all-cause mortality at 90 days.
Full Information
NCT ID
NCT01033916
First Posted
December 16, 2009
Last Updated
January 5, 2022
Sponsor
Inova Health Care Services
1. Study Identification
Unique Protocol Identification Number
NCT01033916
Brief Title
Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery
Acronym
SLIP
Official Title
Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
December 1, 2009 (Actual)
Primary Completion Date
April 30, 2011 (Actual)
Study Completion Date
July 30, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Inova Health Care Services
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research study is designed to better understand post-operative complications as related to the tightness of blood sugar control. It is also hoped that we may learn that a more liberal control of your blood sugars is not inferior to the current strict glucose control. Our ultimate goal is to evaluate if there is any change in the rates of complications between the two groups. We will be comparing the current strict blood glucose control with a more liberal target for blood sugars.
Detailed Description
Hyperglycemia is commonly encountered following cardiac surgery, whether a patient has a history of diabetes or not. Hyperglycemia has been associated with increased perioperative morbidity and mortality; several studies have demonstrated that glycemic control utilizing insulin protocols improves operative mortality, lowers operative morbidity (mediastinitis, atrial fibrillation), and improves long-term survival. However, the optimal target for serum glucose has not been established in post-CABG patients.
Methods:
All CABG patients will be consented prior to surgery. Inclusion criteria for non-diabetic patient is a random fingerstick blood glucose (FSBG) above >150 mg/dL prior, during, or immediately following surgery. All patients with history of diabetes mellitus (Type 1 or Type II) will be immediately eligible for inclusion.
Following CABG surgery, if the patient was started intra-operatively on an insulin infusion, then that patient will be randomized to one of two treatment target groups: Group 1 [Blood Glucose (BG): 80 mg/dL-120 mg/dL] or Group 2 [BG: 121-180 mg/dL]. The randomization design will be a 1:1 allocation of patients between the two groups, with both diabetic and non-diabetic patients enrolled in both arms of the study. Patients will be maintained on an electronic-based protocol of intravenous insulin for a minimum of 72 hrs postoperatively. Patients remaining in the CVICU greater than 72 hrs will have their intravenous insulin continued until transfer to the step-down unit.
The Glucommander© will be programmed to adjust the insulin drip to one of these two target groups. The nursing staff will not be blinded to treatment group allocation. The primary endpoint with be a composite of operative death, major adverse cardiac events (MACE: death, myocardial infarction, re-vascularization), STS Defined Major Morbidity (re-operation, Cerebrovascular accident, Deep Sternal Wound Infection/Mediastinitis, Prolonged Ventilatory Support (> 24 hrs), Acute Renal Failure), and prolonged inotropic support. The pre-specified sub-group analysis will compare perioperative outcome of patients with diabetes vs non-diabetic patients.
Hypothesis:
Our hypothesis is that the perioperative outcome of Group 2 [BG: 121 - 180 mg/dL] will not be inferior to Group 1 [BG: 80-120 mg/dL]. We anticipate significantly more hypoglycemic events in Group 1.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Glucose, Coronary Artery Bypass, Insulin, Coronary Disease
Keywords
Blood Glucose, Insulin/Administration and Dosage, Coronary Artery Bypass
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
STRICT Glucose Control (80-120 mg/dL)
Arm Type
No Intervention
Arm Description
The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
Arm Title
LIBERAL (Target Glucose:121-180 mg/dL)
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
LIBERAL
Intervention Description
The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
Primary Outcome Measure Information:
Title
Operative death, major adverse cardiac events (death, myocardial infarction, re-vascularization), re-operation, Cerebrovascular accident, Deep Sternal Wound Infection, Prolonged Ventilatory Support, Acute Renal Failure, and prolonged inotropic support.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
The second pre-specified endpoint will be all-cause mortality at 90 days.
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
All diabetic patients going for isolated, non-emergent CABG surgery at Inova Fairfax Hospital (IFH).
Non diabetic patients going for isolated, non-emergent CABG Surgery at IFH that are found to have a finger stick blood glucose > 150 mg/dl, either pre-operative, during the procedure or post-operatively.
Those patients that meet Inclusion Criteria #1 OR #2 AND have been started on an insulin infusion while in the operative room will be enrolled.
Exclusion Criteria:
Patients that are not undergoing CABG surgery.
Patients that post-CABG surgery are not on an insulin infusion.
Patients that are undergoing other procedures in addition to CABG will be excluded. (ie. CABG + valve repair)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Niv Ad, MD
Organizational Affiliation
Inova Heart & Vascular Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Inova Fairfax Hospital
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery
We'll reach out to this number within 24 hrs